Skip to main content

Table 2 Risk of hospitalized infections and malignancies associated with abatacept in RA by line of treatment

From: Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study

Outcomes Using inverse probability of treatment weights
Abatacept vs other bDMARDs Abatacept vs csDMARDs
No. of cases/no. of patients* Unadjusted HR (95% CI) Adjusted HR (95% CI) No. of cases/no. of patients* Unadjusted HR (95% CI) Adjusted HR (95% CI)
Hospitalized infections
 Overall 37/1099 vs 25/3138 0.39 (0.17, 0.87) 0.37 (0.18, 0.75) 37/1099 vs 20/1103 0.52 (0.20, 1.39) 0.31 (0.09, 1.05)
 First-line 1/171 vs 13/1191 NR NR 1/171 vs 15/304 NR NR
 Second-line 15/409 vs 7/1132 0.49 (0.23, 1.03) 0.42 (0.18, 0.97) 15/409 vs 4/119 0.99 (0.26, 3.76) NR
 Third- or greater line 21/659 vs 5/1192 0.76 (0.42, 1.38) 0.64 (0.35, 1.15) 21/659 vs 1/50 0.47 (0.13, 1.68) 0.42 (0.09, 2.10)
Malignancies*
 Overall 22/1099 vs 27/3138 2.32 (0.84, 6.44) 1.89 (0.93, 3.84) 22/1099 vs 24/1103 0.77 (0.29, 2.06) 0.93 (0.20, 4.27)
 First-line 3/171 vs 14/1191 NR NR 3/171 vs 17/304 0.75 (0.09, 6.13) 0.36 (0.03, 3.83)
 Second-line 6/409 vs 8/1132 4.61 (0.98, 21.7) NR 6/409 vs 6/119 NR NR
 Third- or greater line 13/659 vs 5/1192 0.35 (0.04, 3.08) 1.34 (0.39, 4.57) 13/659 vs 1/50 0.61 (0.06, 5.75) NR
Non-melanoma skin cancers
 Overall 37/1099 vs 25/3138 1.26 (0.69, 2.29) 1.10 (0.57, 2.11) 37/1099 vs 20/1103 0.90 (0.33, 2.46) 1.05 (0.22, 4.98)
 First-line 1/171 vs 13/1191 NR NR 1/171 vs 15/304 0.88 (0.10, 7.37) 0.62 (0.05, 7.28)
 Second-line 15/409 vs 7/1132 4.08 (0.80, 20.67) NR 15/409 vs 4/119 NR NR
 Third- or greater line 21/659 vs 5/1192 0.35 (0.0, 3.08) 1.34 (0.39, 4.57) 21/659 vs 1/50 0.61 (0.06, 5.75) NR
  1. *Patients with prior history of malignancy were excluded
  2. Using inverse probability of treatment weights with further adjustment for time-varying age and disease duration, HAQ-DI, pain and patient global scores, RDCI and GC treatment duration
  3. bDMARD biologic synthetic disease-modifying antirheumatic drug, CI confidence interval, csDMARD conventional synthetic disease-modifying antirheumatic drug, GC glucocorticoid, HAQ-DI Health Assessment Questionnaire-Disability Index, HR hazard ratio, NR not reported due to low event numbers causing inability to achieve convergence, RA rheumatoid arthritis, RCDI Rheumatic Disease Comorbidity Index
\